Core Insights - Quanterix Corporation announced leadership and governance changes to support its next growth phase, including the appointment of Garret Hampton and Alan Sachs to the Board of Directors [1][2][5] - Bill Donnelly has been appointed as Executive Chair, while Jeffrey Elliott takes on the role of Lead Independent Director [2][3] - The Board now consists of nine members, with seven being independent, following the departure of Paul Meister and David Walt [4][6] Leadership Changes - Garret Hampton, Ph.D., previously President of Clinical Next Generation Sequencing and Oncology at Thermo Fisher Scientific, brings over 35 years of experience in life sciences and diagnostics [7] - Alan Sachs, M.D., Ph.D., former Chief Medical Officer and Chief Scientific Officer at Thermo Fisher Scientific, has over two decades of experience in molecular diagnostics [8] - Bill Donnelly, now Executive Chair, will collaborate closely with the leadership team to support strategic initiatives, including the expansion of biomarker offerings and the launch of LucentAD Complete for Alzheimer's diagnosis [3][5] Strategic Focus - The leadership changes are aimed at advancing Quanterix's strategic initiatives, particularly in expanding its blood- and tissue-based biomarker menu and leveraging synergies from the Akoya acquisition [3][6] - The company is entering a new era post-Akoya acquisition, with confidence in delivering value to shareholders and stakeholders [6]